1
|
Hnilicova P, Grendar M, Turcanova Koprusakova M, Trancikova Kralova A, Harsanyiova J, Krssak M, Just I, Misovicova N, Hikkelova M, Grossmann J, Spalek P, Meciarova I, Kurca E, Zilka N, Zelenak K, Bogner W, Kolisek M. Brain of miyoshi myopathy/dysferlinopathy patients presents with structural and metabolic anomalies. Sci Rep 2024; 14:19267. [PMID: 39164335 DOI: 10.1038/s41598-024-69966-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2024] [Accepted: 08/12/2024] [Indexed: 08/22/2024] Open
Abstract
Miyoshi myopathy/dysferlinopathy (MMD) is a rare muscle disease caused by DYSF gene mutations. Apart from skeletal muscles, DYSF is also expressed in the brain. However, the impact of MMD-causing DYSF variants on brain structure and function remains unexplored. To investigate this, we utilized magnetic resonance (MR) modalities (MR volumetry and 31P MR spectroscopy) in a family with seven children, four of whom have the illness. The MMD siblings showed distinct differences from healthy controls: (1) a significant (p < 0.001) right-sided volume asymmetry (+ 232 mm3) of the inferior lateral ventricles; and (2) a significant (p < 0.001) decrease in [Mg2+], along with a modified energy metabolism profile and altered membrane turnover in the hippocampus and motor and premotor cortices. The patients' [Mg2+], energy metabolism, and membrane turnover measures returned to those of healthy relatives after a month of 400 mg/day magnesium supplementation. This work is the first to describe anatomical and functional abnormalities characteristic of neurodegeneration in the MMD brain. Therefore, we call for further examination of brain functions in larger cohorts of MMD patients and testing of magnesium supplementation, which has proven to be an effective corrective approach in our study.
Collapse
Affiliation(s)
- Petra Hnilicova
- Jessenius Faculty of Medicine in Martin, Biomedical Centre Martin, Comenius University in Bratislava, Mala Hora 4D, 03601, Martin, Slovakia
| | - Marian Grendar
- Jessenius Faculty of Medicine in Martin, Biomedical Centre Martin, Comenius University in Bratislava, Mala Hora 4D, 03601, Martin, Slovakia
| | - Monika Turcanova Koprusakova
- Clinic of Neurology, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Kollarova 2, 03601, Martin, Slovakia
| | - Alzbeta Trancikova Kralova
- Jessenius Faculty of Medicine in Martin, Biomedical Centre Martin, Comenius University in Bratislava, Mala Hora 4D, 03601, Martin, Slovakia
| | - Jana Harsanyiova
- Jessenius Faculty of Medicine in Martin, Biomedical Centre Martin, Comenius University in Bratislava, Mala Hora 4D, 03601, Martin, Slovakia
| | - Martin Krssak
- Department of Biomedical Imaging and Image-Guided Therapy, High-Field MR Center, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria
- Department of Internal Medicine III, Division of Endocrinology and Metabolism, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria
| | - Ivica Just
- Department of Internal Medicine III, Division of Endocrinology and Metabolism, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria
| | | | | | - Jan Grossmann
- Clinic of Neurology, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Kollarova 2, 03601, Martin, Slovakia
| | - Peter Spalek
- Center for Neuromuscular Disease, Clinic of Neurology, University Hospital Bratislava, Slovak Medical University in Bratislava, Pazitkova 4, 83303, Bratislava, Slovakia
| | - Iveta Meciarova
- Department of Pathology, Unilabs Slovensko Patologia s.r.o., Ruzinovska 6, 82606, Bratislava, Slovakia
| | - Egon Kurca
- Clinic of Neurology, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Kollarova 2, 03601, Martin, Slovakia
| | - Norbert Zilka
- Institute of Neuroimmunology, Slovak Academy of Sciences, Dubravska Cesta 5779/9, 84510, Bratislava, Slovakia
| | - Kamil Zelenak
- Clinic of Radiology, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Kollarova 2, 03601, Martin, Slovakia
| | - Wolfgang Bogner
- Department of Biomedical Imaging and Image-Guided Therapy, High-Field MR Center, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria
| | - Martin Kolisek
- Jessenius Faculty of Medicine in Martin, Biomedical Centre Martin, Comenius University in Bratislava, Mala Hora 4D, 03601, Martin, Slovakia.
| |
Collapse
|
2
|
Motta IA, Gouveia ML, Braga AP, Andrade RS, Montenegro MF, Gurgel SN, Albuquerque KM, Souto PA, Cardoso FP, Araujo JS, Pinheiro MC, da Silva CE, Gurgel PA, Feder D, Perez MM, da Veiga GL, Alves BC, Fonseca FL, Carvalho AA. High Prevalence of a c.5979dupA Variant in the Dysferlin Gene (DYSF) in Individuals from a Semiarid Region of Brazil. Curr Genomics 2023; 24:330-335. [PMID: 38235354 PMCID: PMC10790335 DOI: 10.2174/0113892029257856231013115036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2023] [Revised: 07/04/2023] [Accepted: 09/20/2023] [Indexed: 01/19/2024] Open
Abstract
Background Dysferlinopathies represent a group of limb girdle or distal muscular dystrophies with an autosomal-recessive inheritance pattern resulting from the presence of pathogenic variants in the dysferlin gene (DYSF). Objective In this work, we describe a population from a small city in Brazil carrying the c.5979dupA pathogenic variant of DYSF responsible for limb girdle muscular dystrophy type 2R and distal muscular dystrophy. Methods Genotyping analyses were performed by qPCR using customized probe complementary to the region with the duplication under analysis in the DYSF. Results A total of 104 individuals were examined. c.5979dupA was identified in 48 (46.15%) individuals. Twenty-three (22%) were homozygotes, among whom 13 (56.5%) were female. A total of 91.3% (21) of homozygous individuals had a positive family history, and seven (30.4%) reported consanguineous marriages. Twenty-five (24%) individuals were heterozygous (25.8±16 years) for the same variant, among whom 15 (60%) were female. The mean CK level was 697 IU for homozygotes, 140.5 IU for heterozygotes and 176 IU for wild-type homo-zygotes. The weakness distribution pattern showed 17.3% of individuals with a proximal pattern, 13% with a distal pattern and 69.6% with a mixed pattern. Fatigue was present in 15 homozygotes and one heterozygote. Conclusion The high prevalence of this variant in individuals from this small community can be explained by a possible founder effect associated with historical, geographical and cultural aspects.
Collapse
Affiliation(s)
- Isabella A. Motta
- Neurorehabilitation service at Lauro Wanderley University Hospital, João Pessoa, Paraíba, Brazil
| | - Maria L.A. Gouveia
- Neurorehabilitation service at Lauro Wanderley University Hospital, João Pessoa, Paraíba, Brazil
| | - Ana P.M. Braga
- Neurorehabilitation service at Lauro Wanderley University Hospital, João Pessoa, Paraíba, Brazil
| | - Rafael S. Andrade
- Neurorehabilitation service at Lauro Wanderley University Hospital, João Pessoa, Paraíba, Brazil
| | - Mayra F.F. Montenegro
- Neurorehabilitation service at Lauro Wanderley University Hospital, João Pessoa, Paraíba, Brazil
| | - Sandra N. Gurgel
- Neurorehabilitation service at Lauro Wanderley University Hospital, João Pessoa, Paraíba, Brazil
| | - Keila M.F. Albuquerque
- Neurorehabilitation service at Lauro Wanderley University Hospital, João Pessoa, Paraíba, Brazil
| | - Priscilla A.N.G. Souto
- Neurorehabilitation service at Lauro Wanderley University Hospital, João Pessoa, Paraíba, Brazil
| | - Flávia P.B.F. Cardoso
- Neurorehabilitation service at Lauro Wanderley University Hospital, João Pessoa, Paraíba, Brazil
| | - Joseane S. Araujo
- Neurorehabilitation service at Lauro Wanderley University Hospital, João Pessoa, Paraíba, Brazil
| | - Mirella C.L. Pinheiro
- Neurorehabilitation service at Lauro Wanderley University Hospital, João Pessoa, Paraíba, Brazil
| | - Carlos E.P. da Silva
- Neurorehabilitation service at Lauro Wanderley University Hospital, João Pessoa, Paraíba, Brazil
| | - Pamella A.S. Gurgel
- Neurorehabilitation service at Lauro Wanderley University Hospital, João Pessoa, Paraíba, Brazil
| | - David Feder
- Department of Pharmacology, Centro Universitário FMABC, Santo André, SP, Brazil
| | - Matheus M. Perez
- Clinical Analysis Laboratory, Centro Universitário FMABC, Santo André, SP, Brazil
| | - Glaucia L. da Veiga
- Clinical Analysis Laboratory, Centro Universitário FMABC, Santo André, SP, Brazil
| | - Beatriz C.A. Alves
- Clinical Analysis Laboratory, Centro Universitário FMABC, Santo André, SP, Brazil
| | | | - Alzira A.S. Carvalho
- Department of Neurosciences – Neuromuscular service, Centro Universitário FMABC, Santo André, SP, Brazil
| |
Collapse
|
3
|
Yasa J, Reed CE, Bournazos AM, Evesson FJ, Pang I, Graham ME, Wark JR, Nijagal B, Kwan KH, Kwiatkowski T, Jung R, Weisleder N, Cooper ST, Lemckert FA. Minimal expression of dysferlin prevents development of dysferlinopathy in dysferlin exon 40a knockout mice. Acta Neuropathol Commun 2023; 11:15. [PMID: 36653852 PMCID: PMC9847081 DOI: 10.1186/s40478-022-01473-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2022] [Accepted: 11/03/2022] [Indexed: 01/19/2023] Open
Abstract
Dysferlin is a Ca2+-activated lipid binding protein implicated in muscle membrane repair. Recessive variants in DYSF result in dysferlinopathy, a progressive muscular dystrophy. We showed previously that calpain cleavage within a motif encoded by alternatively spliced exon 40a releases a 72 kDa C-terminal minidysferlin recruited to injured sarcolemma. Herein we use CRISPR/Cas9 gene editing to knock out murine Dysf exon 40a, to specifically assess its role in membrane repair and development of dysferlinopathy. We created three Dysf exon 40a knockout (40aKO) mouse lines that each express different levels of dysferlin protein ranging from ~ 90%, ~ 50% and ~ 10-20% levels of wild-type. Histopathological analysis of skeletal muscles from all 12-month-old 40aKO lines showed virtual absence of dystrophic features and normal membrane repair capacity for all three 40aKO lines, as compared with dysferlin-null BLAJ mice. Further, lipidomic and proteomic analyses on 18wk old quadriceps show all three 40aKO lines are spared the profound lipidomic/proteomic imbalance that characterises dysferlin-deficient BLAJ muscles. Collective results indicate that membrane repair does not depend upon calpain cleavage within exon 40a and that ~ 10-20% of WT dysferlin protein expression is sufficient to maintain the muscle lipidome, proteome and membrane repair capacity to crucially prevent development of dysferlinopathy.
Collapse
Affiliation(s)
- Joe Yasa
- grid.413973.b0000 0000 9690 854XKids Neuroscience Centre, The Children’s Hospital at Westmead, Cnr Hawkesbury Road, Hainsworth Street, Westmead, Sydney, NSW 2145 Australia ,grid.414235.50000 0004 0619 2154Functional Neuromics, Children’s Medical Research Institute, Westmead, Sydney, NSW Australia
| | - Claudia E. Reed
- grid.413973.b0000 0000 9690 854XKids Neuroscience Centre, The Children’s Hospital at Westmead, Cnr Hawkesbury Road, Hainsworth Street, Westmead, Sydney, NSW 2145 Australia ,grid.1013.30000 0004 1936 834XDiscipline of Child and Adolescent Health, Faculty of Medicine, University of Sydney, Sydney, NSW Australia
| | - Adam M. Bournazos
- grid.413973.b0000 0000 9690 854XKids Neuroscience Centre, The Children’s Hospital at Westmead, Cnr Hawkesbury Road, Hainsworth Street, Westmead, Sydney, NSW 2145 Australia ,grid.1013.30000 0004 1936 834XDiscipline of Child and Adolescent Health, Faculty of Medicine, University of Sydney, Sydney, NSW Australia
| | - Frances J. Evesson
- grid.413973.b0000 0000 9690 854XKids Neuroscience Centre, The Children’s Hospital at Westmead, Cnr Hawkesbury Road, Hainsworth Street, Westmead, Sydney, NSW 2145 Australia ,grid.414235.50000 0004 0619 2154Functional Neuromics, Children’s Medical Research Institute, Westmead, Sydney, NSW Australia ,grid.1013.30000 0004 1936 834XDiscipline of Child and Adolescent Health, Faculty of Medicine, University of Sydney, Sydney, NSW Australia
| | - Ignatius Pang
- grid.414235.50000 0004 0619 2154Synapse Proteomics, Children’s Medical Research Institute, The University of Sydney, Westmead, NSW Australia
| | - Mark E. Graham
- grid.414235.50000 0004 0619 2154Synapse Proteomics, Children’s Medical Research Institute, The University of Sydney, Westmead, NSW Australia
| | - Jesse R. Wark
- grid.1013.30000 0004 1936 834XOperations, Children’s Medical Research Institute, The University of Sydney, Westmead, NSW Australia
| | - Brunda Nijagal
- grid.1008.90000 0001 2179 088XMetabolomics Australia, Bio21 Institute, The University of Melbourne, Victoria, Australia
| | - Kim H. Kwan
- grid.1008.90000 0001 2179 088XMetabolomics Australia, Bio21 Institute, The University of Melbourne, Victoria, Australia
| | - Thomas Kwiatkowski
- grid.268132.c0000 0001 0701 2416West Chester University, West Chester, PA 19383 USA
| | - Rachel Jung
- grid.412332.50000 0001 1545 0811Department of Physiology and Cell Biology, Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, OH 43210-1252 USA
| | - Noah Weisleder
- grid.412332.50000 0001 1545 0811Department of Physiology and Cell Biology, Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, OH 43210-1252 USA
| | - Sandra T. Cooper
- grid.413973.b0000 0000 9690 854XKids Neuroscience Centre, The Children’s Hospital at Westmead, Cnr Hawkesbury Road, Hainsworth Street, Westmead, Sydney, NSW 2145 Australia ,grid.414235.50000 0004 0619 2154Functional Neuromics, Children’s Medical Research Institute, Westmead, Sydney, NSW Australia ,grid.1013.30000 0004 1936 834XDiscipline of Child and Adolescent Health, Faculty of Medicine, University of Sydney, Sydney, NSW Australia
| | - Frances A. Lemckert
- grid.413973.b0000 0000 9690 854XKids Neuroscience Centre, The Children’s Hospital at Westmead, Cnr Hawkesbury Road, Hainsworth Street, Westmead, Sydney, NSW 2145 Australia ,grid.414235.50000 0004 0619 2154Functional Neuromics, Children’s Medical Research Institute, Westmead, Sydney, NSW Australia ,grid.1013.30000 0004 1936 834XDiscipline of Child and Adolescent Health, Faculty of Medicine, University of Sydney, Sydney, NSW Australia
| |
Collapse
|
4
|
White Z, Milad N, Sellers SL, Bernatchez P. Effect of Dysferlin Deficiency on Atherosclerosis and Plasma Lipoprotein Composition Under Normal and Hyperlipidemic Conditions. Front Physiol 2021; 12:675322. [PMID: 34366880 PMCID: PMC8339577 DOI: 10.3389/fphys.2021.675322] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2021] [Accepted: 06/15/2021] [Indexed: 11/20/2022] Open
Abstract
Dysferlinopathies are a group of muscle disorders caused by mutations to dysferlin, a transmembrane protein involved in membrane patching events following physical damage to skeletal myofibers. We documented dysferlin expression in vascular tissues including non-muscle endothelial cells, suggesting that blood vessels may have an endogenous repair system that helps promote vascular homeostasis. To test this hypothesis, we generated dysferlin-null mice lacking apolipoprotein E (ApoE), a common model of atherosclerosis, dyslipidemia and endothelial injury when stressed with a high fat, and cholesterol-rich diet. Despite high dysferlin expression in mouse and human atheromatous plaques, loss of dysferlin did not affect atherosclerotic burden as measured in the aortic root, arch, thoracic, and abdominal aortic regions. Interestingly, we observed that dysferlin-null mice exhibit lower plasma high-density lipoprotein cholesterol (HDL-C) levels than their WT controls at all measured stages of the disease process. Western blotting revealed abundant dysferlin expression in protein extracts from mouse livers, the main regulator of plasma lipoprotein levels. Despite abnormal lipoprotein levels, Dysf/ApoE double knockout mice responded to cholesterol absorption blockade with lower total cholesterol and blunted atherosclerosis. Our study suggests that dysferlin does not protect against atherosclerosis or participate in cholesterol absorption blockade but regulates basal plasma lipoprotein composition. Dysferlinopathic patients may be dyslipidemic without greater atherosclerotic burden while remaining responsive to cholesterol absorption blockade.
Collapse
Affiliation(s)
- Zoe White
- Department of Anesthesiology, Pharmacology, and Therapeutics, The University of British Columbia, Vancouver, BC, Canada.,UBC Centre for Heart Lung Innovation, St. Paul's Hospital, Vancouver, BC, Canada
| | - Nadia Milad
- Department of Anesthesiology, Pharmacology, and Therapeutics, The University of British Columbia, Vancouver, BC, Canada.,UBC Centre for Heart Lung Innovation, St. Paul's Hospital, Vancouver, BC, Canada
| | - Stephanie L Sellers
- Department of Anesthesiology, Pharmacology, and Therapeutics, The University of British Columbia, Vancouver, BC, Canada.,UBC Centre for Heart Lung Innovation, St. Paul's Hospital, Vancouver, BC, Canada
| | - Pascal Bernatchez
- Department of Anesthesiology, Pharmacology, and Therapeutics, The University of British Columbia, Vancouver, BC, Canada.,UBC Centre for Heart Lung Innovation, St. Paul's Hospital, Vancouver, BC, Canada
| |
Collapse
|